Overall results indicate that p53 mutations often occurred in low grade gliomas (WHO grade II astrocytoma; Bourne and Schiff, 2010) and thus is a frequent event in the pathological progression of secondary glioblastoma (WHO Grade IV; Gladson et al., 2010). Here, TP53 is linked to central nervous system cancer.